DE69714033D1 - Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten - Google Patents

Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten

Info

Publication number
DE69714033D1
DE69714033D1 DE69714033T DE69714033T DE69714033D1 DE 69714033 D1 DE69714033 D1 DE 69714033D1 DE 69714033 T DE69714033 T DE 69714033T DE 69714033 T DE69714033 T DE 69714033T DE 69714033 D1 DE69714033 D1 DE 69714033D1
Authority
DE
Germany
Prior art keywords
ras
lymphoizytes
cytitoxic
muted
generate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69714033T
Other languages
English (en)
Other versions
DE69714033T2 (de
Inventor
Jeffrey Schlom
Scott Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Publication of DE69714033D1 publication Critical patent/DE69714033D1/de
Application granted granted Critical
Publication of DE69714033T2 publication Critical patent/DE69714033T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69714033T 1996-04-19 1997-04-17 Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten Expired - Lifetime DE69714033T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63534496A 1996-04-19 1996-04-19
PCT/US1997/006470 WO1997040156A1 (en) 1996-04-19 1997-04-17 Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes

Publications (2)

Publication Number Publication Date
DE69714033D1 true DE69714033D1 (de) 2002-08-22
DE69714033T2 DE69714033T2 (de) 2003-02-13

Family

ID=24547410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69714033T Expired - Lifetime DE69714033T2 (de) 1996-04-19 1997-04-17 Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten

Country Status (8)

Country Link
US (1) US8883448B2 (de)
EP (1) EP0895538B1 (de)
AT (1) ATE220718T1 (de)
AU (1) AU2734397A (de)
DE (1) DE69714033T2 (de)
DK (1) DK0895538T3 (de)
ES (1) ES2180045T3 (de)
WO (1) WO1997040156A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US6558671B1 (en) 1997-01-30 2003-05-06 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
GB9907860D0 (en) * 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
DK2714071T3 (da) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
CN107075479A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
MA52435A (fr) * 2018-03-02 2021-01-06 Elicio Therapeutics Inc Composés contenant une séquence kras mutante et un lipide et leurs utilisations
EP3914270A4 (de) * 2019-01-25 2023-01-11 The Trustees of the University of Pennsylvania Zusammensetzungen und verfahren zum targeting von mutanten ras
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146633A (en) * 1973-05-07 2000-11-14 The Ohio State University Method for treatment of antigenically modified polypeptides
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
ATE109008T1 (de) 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use

Also Published As

Publication number Publication date
ATE220718T1 (de) 2002-08-15
EP0895538B1 (de) 2002-07-17
AU2734397A (en) 1997-11-12
DE69714033T2 (de) 2003-02-13
EP0895538A1 (de) 1999-02-10
ES2180045T3 (es) 2003-02-01
WO1997040156A1 (en) 1997-10-30
US20100074945A1 (en) 2010-03-25
US8883448B2 (en) 2014-11-11
DK0895538T3 (da) 2002-11-04

Similar Documents

Publication Publication Date Title
DE69714033D1 (de) Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
DE69733610D1 (de) Interleukin-15 antagoniste
DE69324487D1 (de) Rezeptorbindende region des diphtherietoxius
DE69229428D1 (de) Therapeutisch nützliche peptide und peptidfragmente
HUP9801826A2 (hu) HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére
DE59807369D1 (de) Medizinische Bandage
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
ATE217795T1 (de) Saponin-antigen-konjugate und ihre verwendung
IT1229721B (it) Dispositivo di supporto a treppiede inclinabile, in particolare per supportare oggetti come strumenti musicali e/o simili.
DK1210430T3 (da) MUC-1-afledte peptider
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
WO1997035021A3 (en) Prostate specific antigen oligo-epitope peptide
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
HK1028615A1 (en) Isolated nona-and decapeptides which bind to hla molecules, and the use thereof
NO952385D0 (no) Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
BR0110577A (pt) Decorina transgenicamente produzida
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
GB9501826D0 (en) Polypeptide fragments
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
DE3860354D1 (de) Neigungseinstell- und verstellvorrichtung fuer klapp-, lehnstuehle und aehnliche gegenstaende.
EP0836480A4 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität ausweisen und methoden für ihre herstellung und die verwendung derselben
BR0107547A (pt) Receptor
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf

Legal Events

Date Code Title Description
8364 No opposition during term of opposition